Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Myriad Genetics (MYGN) Short-Term Debt issuances: 2018-2025

Historic Short-Term Debt issuances for Myriad Genetics (MYGN) over the last 1 years, with Mar 2025 value amounting to $40.0 million.

  • Myriad Genetics' Short-Term Debt issuances fell 33.33% to $40.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $100.0 million, marking a year-over-year decrease of 47.37%. This contributed to the annual value of $120.0 million for FY2024, which is 50.00% up from last year.
  • As of Q1 2025, Myriad Genetics' Short-Term Debt issuances stood at $40.0 million, which was up 100.00% from $20.0 million recorded in Q4 2024.
  • In the past 5 years, Myriad Genetics' Short-Term Debt issuances registered a high of $60.0 million during Q1 2024, and its lowest value of $20.0 million during Q2 2024.
  • Over the past 3 years, Myriad Genetics' median Short-Term Debt issuances value was $40.0 million (recorded in 2025), while the average stood at $34.3 million.
  • Data for Myriad Genetics' Short-Term Debt issuances shows a maximum YoY plummeted of 50.00% (in 2024) over the last 5 years.
  • Myriad Genetics' Short-Term Debt issuances (Quarterly) stood at $40.0 million in 2023, then plummeted by 50.00% to $20.0 million in 2024, then tumbled by 33.33% to $40.0 million in 2025.
  • Its Short-Term Debt issuances stands at $40.0 million for Q1 2025, versus $20.0 million for Q4 2024 and $20.0 million for Q3 2024.